1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Discovery of the Genetic Basis of Childhood Cancers and of Effective Treatments (R01) is sponsored by National Cancer Institute (NCI). Supports research on pediatric cancer genomics and precision medicine, with specific priority given to AI-driven data analysis under the Childhood Cancer Data Initiative.
Get alerted about grants like this
Get emailed when new opportunities from “National Cancer Institute (NCI)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Nonprofits, Universities, and Small Businesses. Confirm the full requirements in the official notice before applying.
The current listing shows up to $500,000 per year. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was February 5, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Discovery of the Genetic Basis of Childhood Cancers and of Effective Treatments (R01) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required) is sponsored by National Cancer Institute (NCI). This opportunity from the National Cancer Institute (NCI) is for the Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations. This is a cooperative agreement (UM1) and requires a clinical trial.